Asthma costs and social impact

 
Carlos Nunes, Ana Margarida Pereira and Mário Morais-Almeida

Abstract

In recent decades, both asthma prevalence and incidence have been increasing worldwide, not only due to the genetic background, but mainly because of the effect of a wide number of environmental and lifestyle risk factors.

In many countries noncommunicable diseases, like asthma, are not yet considered a healthcare priority. This review will analyze and discuss disparities in asthma management in several countries and regions, such as access to healthcare human resources and medications, due to limited financial capacity to develop strategies to control and prevent this chronic disease.

This review tries to explore the social and economic burden of asthma impact on society. Although asthma is generally accepted as a costly illness, the total costs to society (direct, indirect and intangible asthma costs) are difficult to estimate, mainly due to different disease definitions and characterizations but also to the use of different methodologies to assess the asthma socio-economic impact in different societies.

The asthma costs are very variables from country to country, however we can estimate that a mean cost per patient per year, including all asthmatics (intermittent, mild, moderate and severe asthma) in Europe is $USD 1,900, which seems lower than USA, estimated mean $USD 3,100.

Download PDF

 

 

(You must be logged in to add and reply comments)

Interasma on Twitter

Interasma RT @Aller_MD: “JAK Inhibitors Showing Promise for Many Skin Problems Conditions ranging from alopecia to vitiligo” https://t.co/mSR0or0JM5
6hreplyretweetfavorite
Interasma RT @Aller_MD: Top story: Carina Venter PhD RD on Twitter: "A few months ago Cat’s in the Crad… https://t.co/hSf86Y42Qo, see more https://t.…
6hreplyretweetfavorite
Interasma RT @Aller_MD: “Mechanistic insights on topical tacrolimus for the treatment of atopic dermatitis” https://t.co/YFs34eAADf https://t.co/UZMa
6hreplyretweetfavorite
Interasma RT @Aller_MD: Upper and lower airway remodelling mechanisms in #asthma, #allergic rhinitis and chronic #rhinosinusitis: the one airway conc…
6hreplyretweetfavorite
Interasma RT @Aller_MD: Hot Topics: Recent Developments in Dermatologic Therapies https://t.co/w5mnT5B566 https://t.co/Vj5jJmgoO6
11hreplyretweetfavorite

Editor: Juan C. Ivancevich, MD

Copyright © Interasma 2003-2017  •  Terms of Use  •  Privacy Policy  •  Contact Us  •  Sitemap

Powered by FREI SA

InterAsma